fasudil has been researched along with Neoplasms in 4 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All 21 drugs are orally bioavailable or topically effective." | 3.01 | Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States. ( Roskoski, R, 2023) |
| "Approximately 30% of human cancers harbor oncogenic gain-of-function mutations in KRAS." | 1.38 | STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. ( Carr, SA; Fröhling, S; Golub, TR; Jaffe, JD; Luo, T; Masson, K; Ross, NT; Scherer, CA; Scholl, C; Schreiber, SL; Silkworth, W; Stern, AM, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roskoski, R | 1 |
| Lu, Q | 1 |
| Longo, FM | 1 |
| Zhou, H | 1 |
| Massa, SM | 1 |
| Chen, YH | 1 |
| Iorio, F | 1 |
| Bosotti, R | 1 |
| Scacheri, E | 1 |
| Belcastro, V | 1 |
| Mithbaokar, P | 1 |
| Ferriero, R | 1 |
| Murino, L | 1 |
| Tagliaferri, R | 1 |
| Brunetti-Pierri, N | 1 |
| Isacchi, A | 1 |
| di Bernardo, D | 1 |
| Luo, T | 1 |
| Masson, K | 1 |
| Jaffe, JD | 1 |
| Silkworth, W | 1 |
| Ross, NT | 1 |
| Scherer, CA | 1 |
| Scholl, C | 1 |
| Fröhling, S | 1 |
| Carr, SA | 1 |
| Stern, AM | 1 |
| Schreiber, SL | 1 |
| Golub, TR | 1 |
1 review available for fasudil and Neoplasms
| Article | Year |
|---|---|
Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Humans; Neoplasms; Protein Kin | 2023 |
3 other studies available for fasudil and Neoplasms
| Article | Year |
|---|---|
Signaling through Rho GTPase pathway as viable drug target.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Aminoquinolines; Anilides; Animals; Benzamide | 2009 |
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Antineoplastic Agents; Autophagy; Blottin | 2010 |
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Biological Assay; Biomarkers, Tumor; Cell Line, Tumor | 2012 |